Upon reviewing all leading diabetes treatment guidelines, it is clear that there are definite recommendations and rationale for using SGLT-2 and DPP-IV inhibitors as the preferred add-on OADs in T2DM patients with established CVD, CKD, HF, or with multiple risk factors. This evidence concerns the gene SLC5A2 and diabetes mellitus.